Another use of silica gel and aqueous eluent for HPLC analysis of clozapine and desmethylclozapine

Journal of Analytical Toxicology

Volumn 23, Issue 3, 1999, Pages 195-199

  Coudoré, François ^a,b   Nicolay, Alain ^a   Hoareau, Monique ^a   Eschalier, Alain ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

^b Lab Pharmacologie Clin Toxicologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NORCLOZAPINE;

ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; QUANTITATIVE ASSAY; SCHIZOPHRENIA;

EID: 0032984315     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/23.3.195     Document Type: Article

References (32)

1. D.J. Freeman and L.K. Oyewumi. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin. Pharmacokinet. 32: 93-100 (1997).
2. T.B. Cooper. Clozapine plasma level monitoring: current status. Psychiatr. Q. 67(4): 297-311 (1996).
3. D.D. Miller, F. Fleming, T.L. Holman, and P.J. Perry. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J. Clin. Psychol. 55(9): 117-121 (1994).
4. P.J. Perry, D.D. Miller, S.V. Arndt, and R.J. Cadoret. Clozapine and desmethyl-clozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am. J. Psychol. 148: 231-235 (1991).
5. M.H. Kronig, R.A. Munne, S. Szymanski, A.Z. Safferman, S. Pollack, T. Cooper, J.M. Kane, and J.A. Lieberman. Plasma clozapine levels and clinical response for treatment refractory schizophrenic patients. Am. J. Psychol. 152: 179-182 (1995).
6. S.G. Potkin, R. Bera, B. Gulasekaram, J. Costa, S. Hayes, G. Richmond, D. Carreon, K. Sitanggan, and B. Berber. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J. Clin. Psychol. 55(9): 133-136 (1994).
7. P. Preterre. Clozapinemie et ajustement therapeutique, Encephale 13: 53-57 (1997).
8. C. Haring, U. Meise, C. Humpel, A. Saria, W.W. Fleischhacker, and H. Hinterhuber. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacol. 99: S38-S40 (1989).
9. T.A. Jennison, P. Brown, J. Crossett, M. Kushnir, and F.M. Urry. A rapid gas chromatographic method quantitating clozapine in human plasma or serum for the purpose of therapeutic monitoring. J. Anal. Toxicol. 19: 537-540 (1995).
10. M.J. Lovdahl, P.J. Perry, and D.D. Miller. The assay of clozapine and N-desmethyl-clozapine in human plasma by high-performance liquid chromatography. Ther. Drug Monit. 13: 69-72 (1991).
11. H. Weigmann and C. Hiemke. Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. Biomed. Appl. 583: 209-216 (1992).
12. O.V. Olesen and B. Poulsen. On-line fully automated determination of clozapine and desmethyl-clozapine in human serum by solid-phase extraction on exchangeable cartridges and liquid chromatography using a methanol buffer mobile phase on unmodified silica. J. Chromatogr. Biomed. Appl. 622: 39-46 (1993).
13. G. Dollo, H. Bun, and M. Bonnefont-Cornet. Dosage de la clozapine plasmatique par chromatographie en phase liquide et applications au suivi thérapeutique. J. Pharma. Clin. 13: 17-22 (1994).
14. R.M. Gupta. Column liquid chromatographic determination of clozapine and N-desmethyl clozapine in human serum using solid-phase exfraction. J. Chromatogr Biomed. Appl. 673: 311-315 (1995).
15. P.T. McCarthy, S. Hughes, and C. Paton. Measurement of clozapine and desmethyl-clozapine in plasma/serum by high performance liquid chromatography with ultraviolet detection. Biomed. Appl. 9: 36-41 (1995).
16. E.O. Fadiran, J. Leslie, M. Fossler, and D. Young. Determination of clozapine and its major metabolites in human serum and rat plasma by liquid chromatography using solid-phase extraction and ultraviolet detection. J. Pharmacol. Biomed. Anal. 13(2): 185-190 (1995).
17. H.C Liu, W.H. Chang, F.C. Wei, S.-K. Lin, S.-K. Lin, and M.W. Jann. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther. Drug Monit. 18: 200-207 (1996).
18. N. Aymard, C. Baldacci, A. Leyris, P.O. Smagghe, S. Triboulet, M.N. Vacheron, A.Viala, and F. Caroli. Neuroleptic-resistant schizophrenic patients treated by clozapine: clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels. Therapie 52: 227-232 (1997).
19. C. Guitton, J.M. Kinowski, R. Aznar, and F. Bressolle. Determination of clozapine and its major metabolites in human plasma and red blood cells by high-performance liquid chromatography with ultraviolet absorbance detection. J. Chromatogr. 690: 211-222 (1997).
20. K.K. Akerman. Analysis of clozapine and norclozapine by high-performance liquid chromatography. J. Chromatogr. 696: 253-259 (1997).
21. S. Mady, P. Wax, D. Wang, C. Goetz, C. Hadley, and R. Love. Pediatric clozapine intoxication. Am. J. Emerg. Med. 14(5): 462-463 (1996).
22. J.E. Meeker, P.W. Herrmann, C.W. Som, and P.C. Reynolds. Clozapine tissue concentrations following an apparent suicidal overdose of Clozaril®. J. Anal. Toxicol. 16: 54-56 (1992).
23. K. Worm, B. Kringsholm, and A. Steentoft. Clozapine cases with fatal, toxic or therapeutic concentrations. Int. J. Leg. Med. 106: 115-118 (1993).
24. D. Reith, J.P.R. Monteleone, I.M. Whyte, W. Ebelling, N.H.G. Holford, and G.L. Carter. Features and toxicokinetics of clozapine in overdose. Ther. Drug. Monit. 20: 92-97 (1998).
25. B.A. Bidlingmeyer, J.K. Del Rios, and J. Korpi. Separation of organic amines compounds on silica gel using reversed-phase eluents. Anal. Chem. 54: 442-448 (1982).
26. B. Law. Analysis of basic compounds on a silica column with an aqueous methanol eluent. The use of quantitative structure-retention relationships in metabolite identification. J. Chromatogr. 407: 1-18 (1987).
27. R.M. Smith, T.G. Hurdley, J.P. Westlake, R. Gill, and M.D. Osselton. Retention reproducibility of basic drugs in high-performance liquid chromatography on a silica column with a methanol-high-pH buffer eluent. Batch-to-batch reproducibility of the stationary phase. J. Chromatogr. 455: 77-93 (1988).
28. R. Gill, M.D. Osselton, and R.M. Smith. International collaborative study of the retention reproducibility of basic drugs in high-performance liquid chromatography on a silica colum with a methanol-ammonium nitrate eluent. J. Chromatogr. Biomed. Anal. 7: 447-457 (1989).
29. R.M. Smith, J.P. Westlake, R. Gill, and M.D. Osselton. Retention reproducibility of basic drugs in high-performance liquid chromatography on a silica column with a methanol-high-pH buffer eluent. J. Chromatogr. 592: 85-92 (1992).
30. B.A. Bidlingmeyer, J. Korpi, and J.N. Little. Determination of tricyclic antidepressants using silica gel with a reversed-phase eluent. Chromatographia 15: 835 (1982).
31. F. Coudoré, D. Ardid, A. Eschalier, J. Fialip, and J. Lavarenne. High-performance liquid chromatographic determination of amitriptyline and its main metabolites using a silica column with reversed-phase eluent. J. Chramatogr. 584: 249-255 (1992).
32. F. Coudoré, F. Hourcade, C. Molinier-Manoukian, A. Eschalier, and 'J. Lavarenne. Application of HPLC with silica-phase and reversed-phase eluents for the determination of clomipramine and demethylated and 8-hydroxylated metabolites. J. Anal. Toxicol. 20: 101-105 (1996).